Homologous recombination pathway alterations in basal-like breast cancer

By
Simon Aho
Boris Guyot
Véronique Maguer-Satta
June 18, 2026
0 min

Frontiers In Oncology

Overview

This report examines the alterations in the homologous recombination (HR) pathway in basal-like breast carcinoma (BLBC), highlighting its association with genomic instability and poor prognosis. The findings suggest that HR deficiency (HRD) may be enriched in BLBC, with implications for therapeutic strategies.

Background

Breast cancer is a heterogeneous disease with various molecular subtypes, including basal-like breast carcinoma (BLBC), which accounts for 15-20% of cases and is linked to poor outcomes. Understanding the molecular mechanisms underlying HRD in BLBC is crucial, as it may influence treatment responses and patient management. The similarities between BLBC and BRCA1-deficient tumors underscore the importance of exploring HRD in this subtype.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

BLBC is characterized by high genomic instability and aggressive clinical behavior.
HRD may be enriched in BLBC due to various mechanisms beyond BRCA1/2 mutations.
Current HRD detection methods are critical for understanding its role in BLBC.
There is a need for future studies to clarify the clinical relevance of HRD in molecularly defined cohorts.
BLBC shares several histo-molecular characteristics with BRCA1-deficient tumors.

Clinical Implications

Healthcare professionals should consider the potential for HRD in patients with BLBC when determining treatment strategies. The identification of HRD may guide the use of DNA-damaging agents and PARP inhibitors, although further research is needed to establish its clinical utility.

Conclusion

The exploration of HRD in basal-like breast carcinoma presents both challenges and opportunities for improving patient outcomes. Continued research is essential to translate these findings into clinically actionable strategies.